Luca Borradori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7383973/publications.pdf

Version: 2024-02-01

247 papers

11,711 citations

25034 57 h-index 95 g-index

271 all docs

271 docs citations

times ranked

271

7391 citing authors

#	Article	IF	CITATIONS
1	Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy. RMD Open, 2022, 8, e002166.	3.8	15
2	Development of pemphigus vulgaris following mRNA SARSâ€CoVâ€19 BNT162b2 vaccination in an 89â€yearâ€old patient. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	l 2.4	10
3	New onset of sarcoidosis after <scp>COVID</scp> â€19 infection. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	4
4	Deciphering the Contribution of BP230 Autoantibodies in Bullous Pemphigoid. Antibodies, 2022, 11, 44.	2.5	4
5	Updated <scp>S2</scp> K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (<scp>EADV</scp>). Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1689-1704.	2.4	61
6	Brunsting-Perry pemphigoid: A retrospective case series of a frequently unrecognized condition. Journal of the American Academy of Dermatology, 2021, 85, 1324-1326.	1.2	5
7	Neutrophilic dermatosis of the dorsal hands triggered by mechanical trauma. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e20-e21.	2.4	5
8	A relapsing localized variant of neutrophilic dermatosis triggered by tissue injury. British Journal of Dermatology, 2021, 184, 162-164.	1.5	2
9	Neutrophilic dermatoses with unusual and atypical presentations. Clinics in Dermatology, 2021, 39, 261-270.	1.6	6
10	Prurigo Pigmentosa: Demographics and Characteristics in 14 Caucasian Patients. Dermatology, 2021, 237, 878-883.	2.1	4
11	How to diagnose bullous pemphigoid and its variants: the question is still open. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e434-e435.	2.4	2
12	Mixed Individual-Aggregate Data on All-Cause Mortality in Bullous Pemphigoid. JAMA Dermatology, 2021, 157, 421.	4.1	15
13	European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1750-1764.	2.4	72
14	European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1926-1948.	2.4	86
15	Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatology, The, 2021, 3, e789-e797.	3.9	179
16	Case Report: Genetic Double Strike: VEXAS and TET2-Positive Myelodysplastic Syndrome in a Patient With Long-Standing Refractory Autoinflammatory Disease. Frontiers in Immunology, 2021, 12, 800149.	4.8	23
17	Diagnosis and management of pemphigus: Recommendations of an international panel of experts. Journal of the American Academy of Dermatology, 2020, 82, 575-585.e1.	1.2	224
18	Mepolizumab failed to affect bullous pemphigoid: A randomized, placeboâ€controlled, doubleâ€blind phase 2 pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 669-672.	5.7	44

#	Article	IF	CITATIONS
19	Mucous membrane pemphigoid and lichenoid reactions after immune checkpoint inhibitors: common pathomechanisms. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e112-e115.	2.4	18
20	Oral lichen planus and oral lichenoid lesions – an analysis of clinical and histopathological features. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e104-e107.	2.4	15
21	Reverse Phenotyping in Patients with Skin Capillary Malformations and Mosaic GNAQ or GNA11 Mutations Defines a Clinical Spectrum with Genotype-Phenotype Correlation. Journal of Investigative Dermatology, 2020, 140, 1106-1110.e2.	0.7	30
22	Herpetiform aphthous ulcerations induced by secukinumab: Report of 2 cases. JAAD Case Reports, 2020, 6, 1107-1109.	0.8	1
23	Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1900-1913.	2.4	159
24	The evolving field of Dermatoâ€oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV–UEMS and EORTC Cutaneous Lymphoma Task Force. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2183-2197.	2.4	22
25	Herpes zoster of the trigeminal nerve with multi-dermatomal involvement: a case report of an unusual presentation. BMC Dermatology, 2020, 20, 12.	2.1	7
26	Detection of autoantibodies against alpha-2-macroglobulin-like 1 in paraneoplastic pemphigus sera utilizing novel green fluorescent protein-based immunoassays. Journal of Dermatological Science, 2020, 98, 173-178.	1.9	6
27	Diagnostic performance of direct immunofluorescence microscopy studies by biopsy sites in autoimmune subepidermal blistering dermatoses: a prospective study. British Journal of Dermatology, 2020, 183, 970-972.	1.5	2
28	Pterygium in bullous pemphigoid: An unusual complication. JAAD Case Reports, 2020, 6, 737-739.	0.8	2
29	Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid. Frontiers in Immunology, 2020, 11, 611549.	4.8	33
30	Patterns among Patients with Chronic Pruritus: A Retrospective Analysis of 170 Patients. Acta Dermato-Venereologica, 2020, 100, adv00068.	1.3	5
31	Ulceration and Alopecia of the Scalp Owing to C2 Radiculoneuropathy Following Posterior Atlanto-Axial Fixation. JAMA Dermatology, 2019, 155, 981.	4.1	0
32	Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2313-2318.	2.4	2
33	Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid. Frontiers in Immunology, 2019, 10, 1919.	4.8	32
34	Human "T _H 9―cells are a subpopulation of PPAR-γ ⁺ T _H 2 cells. Science Immunology, 2019, 4, .	11.9	75
35	Emergency Consultations in Dermatology in a Secondary Referral Hospital in Southern Switzerland: A Prospective Cross-Sectional Analysis. Dermatology, 2019, 235, 243-249.	2.1	6
36	Mucous membrane pemphigoid of the oral lichen type: a retrospective analysis of 16 cases. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e205-e207.	2.4	13

#	Article	IF	CITATIONS
37	Subcutaneous Injection of Large Volumes of Polidocanol. Dermatologic Surgery, 2019, 45, 476-477.	0.8	5
38	Pushing and loss of elastic fibers are highly specific for melanoma and rare in melanocytic nevi. Archives of Dermatological Research, 2019, 311, 99-107.	1.9	2
39	Subacute cutaneous lupus erythematosus triggered by an antiviral treatment combination for hepatitis C virus infection. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e129-e131.	2.4	8
40	Gender and age significantly determine patient needs and treatment goals in psoriasis $\hat{a} \in \hat{a}$ a lesson for practice. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 700-708.	2.4	78
41	Prioritizing topics in guideline development: results of a twoâ€phase online survey of dermatologist members of the <scp>EADV</scp> . Journal of the European Academy of Dermatology and Venereology, 2019, 33, 227-233.	2.4	5
42	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. Journal of Investigative Dermatology, 2019, 139, 31-37.	0.7	55
43	Rituximab as first-line adjuvant therapy for pemphigus: Retrospective analysis of long-term outcomes at a single center. Journal of the American Academy of Dermatology, 2018, 78, 806-808.	1.2	32
44	Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland. Journal of the American Academy of Dermatology, 2018, 78, 1090-1096.	1.2	127
45	Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e256-e257.	2.4	27
46	Patterns of chronic hand eczema: a semantic map analysis of the <scp>CARPE</scp> registry data. British Journal of Dermatology, 2018, 178, 229-237.	1.5	22
47	Monocytes enhance neutrophilâ€induced blister formation in an ex vivo model of bullous pemphigoid. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1119-1130.	5.7	40
48	The expanding spectrum of clinical phenotypes associated with <i>PSTPIP1</i> mutations: from PAPA to PAMI syndrome and beyond. British Journal of Dermatology, 2018, 178, 982-983.	1.5	25
49	Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management. Clinical Reviews in Allergy and Immunology, 2018, 54, 26-51.	6.5	158
50	Rituximab and bilateral HSV epithelial keratitis in a patient with mucous membrane pemphigoid. Journal of Ophthalmic Inflammation and Infection, 2018, 8, 12.	2.2	9
51	Application of electrochemotherapy in the management of primary and metastatic cutaneous malignant tumours: a systematic review and meta-analysis. European Journal of Dermatology, 2018, 28, 287-313.	0.6	28
52	Desmoplakin Gene Variants and Risk for Arrhythmogenic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, e002241.	3.6	11
53	Desmoplakin interacts with the coil 1 of different types of intermediate filament proteins and displays high affinity for assembled intermediate filaments. PLoS ONE, 2018, 13, e0205038.	2.5	4

Superficial Neutrophilic Dermatoses: From Subcorneal Pustular Dermatosis (Sneddon-Wilkinson) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6

#	Article	IF	CITATIONS
55	Chronic hand eczema: A prospective analysis of the Swiss CARPE registry focusing on factors associated with clinical and quality of life improvement. Contact Dermatitis, 2018, 79, 136-148.	1.4	14
56	Reply to: "Bullous pemphigoid and diabetes mellitus: Are we missing the larger picture?― Journal of the American Academy of Dermatology, 2018, 79, e29-e30.	1.2	0
57	Factors influencing sessions' and speakers' evaluation: an analysis of seven consecutive European Academy of Dermatology and Venereology congress editions. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2307-2313.	2.4	1
58	006 TGF- \hat{l}^2 - and IL-4-induced PPAR- \hat{l}^3 promotes IL-9 expression in human TH2 cells. Journal of Investigative Dermatology, 2018, 138, S1.	0.7	0
59	A recessive mutation in the <i>DSP</i> gene linked to cardiomyopathy, skin fragility and hair defects impairs the binding of desmoplakin to epidermal keratins and the muscle-specific intermediate filament desmin. British Journal of Dermatology, 2018, 179, 797-799.	1.5	17
60	Re: risk of malignancy and systemic absorption after application of topical tacrolimus in oral lichen planus. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e85-e86.	2.4	2
61	Management of facial papular elastosis by a new generation of dualâ€mode erbium: yttrium aluminium garnet (Er–YAG) laser: report of a case. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e1-e2.	2.4	0
62	Prurigo Pigmentosa in White Monozygotic Twins. JAMA Dermatology, 2017, 153, 353.	4.1	7
63	Evidence for a role of eosinophils in blister formation in bullous pemphigoid. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1105-1113.	5.7	85
64	Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016. Journal of Investigative Dermatology, 2017, 137, 1199-1203.	0.7	34
65	Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid. Dermatology, 2017, 233, 401-403.	2.1	30
66	Eosinophils as putative therapeutic targets in bullous pemphigoid. Experimental Dermatology, 2017, 26, 1187-1192.	2.9	29
67	Canakinumab for Severe Hidradenitis Suppurativa. JAMA Dermatology, 2017, 153, 1195.	4.1	45
68	The Cutaneous Spectrum of Lupus Erythematosus. Clinical Reviews in Allergy and Immunology, 2017, 53, 291-305.	6.5	83
69	Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence?. Current Opinion in Oncology, 2017, 29, 129-135.	2.4	35
70	Mutations in <i><scp>POGLUT</scp>1</i> in Galli–Galli/Dowling–Degos disease. British Journal of Dermatology, 2017, 176, 270-274.	1.5	17
71	The pathogenesis of pemphigus: Controversy vs complexity. Experimental Dermatology, 2017, 26, 1271-1273.	2.9	7
72	Treatment of sporadic portâ€wine stains: a retrospective review of 17 cases consecutively treated by pulsed sequential dual wavelength 595 and 1064 nm laser. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 557-563.	2.4	4

#	Article	IF	Citations
73	Distinct interferonâ€gamma and interleukinâ€9 expression in cutaneous and oral lichen planus. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 880-886.	2.4	23
74	Development of a Novel Green Fluorescent Protein-Based Binding Assay to Study the Association of Plakins with Intermediate Filament Proteins. Methods in Enzymology, 2016, 569, 117-137.	1.0	6
75	Diagnostic value of immunohistochemistry on formalin-fixed, paraffin-embedded skin biopsy specimens for bullous pemphigoid. British Journal of Dermatology, 2016, 175, 988-993.	1.5	20
76	Calculation of cutâ€off values based on the Autoimmune Bullous Skin Disorder Intensity Score () Tj ETQq0 0 0 for defining moderate, significant and extensive types of pemphigus. British Journal of Dermatology, 2016, 175, 142-149.	rgBT /Over 1.5	lock 10 Tf 50 68
77	Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT. Dermatology, 2016, 232, 640-647.	2.1	32
78	Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. Dermatology, 2016, 232, 385-406.	2.1	39
79	Rituximab for the Treatment of Isolated Refractory Desquamative Gingivitis Due to Mucous Membrane Pemphigoid. JAMA Dermatology, 2016, 152, 1396.	4.1	6
80	One gene but different proteins and diseases: the complexity of dystonin and bullous pemphigoid antigen 1. Experimental Dermatology, 2016, 25, 10-16.	2.9	80
81	Bowen disease of the nail unit: a retrospective study of 12 cases and their association with human papillomaviruses. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1503-1506.	2.4	30
82	Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management. Drugs and Aging, 2016, 33, 711-723.	2.7	10
83	Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases. British Journal of Dermatology, 2016, 175, 1382-1386.	1.5	112
84	Medical, psychological and socioâ€economic implications of chronic hand eczema: a crossâ€sectional study. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 628-637.	2.4	34
85	Immune response in pemphigus and beyond: progresses and emerging concepts. Seminars in Immunopathology, 2016, 38, 57-74.	6.1	68
86	Cutaneous Collagenous Vasculopathy: A Rare Form of Microangiopathy Successfully Treated with a Combination of Multiplex Laser and Optimized Pulsed Light with a Review of the Literature. Dermatology, 2016, 232, 107-111.	2.1	13
87	Ultraviolet radiation protection and skin cancer awareness in recreational athletes: a survey among participants in a running event. Swiss Medical Weekly, 2016, 146, w14297.	1.6	15
88	Diagnostic delay in hidradenitis suppurativa is a global problem. British Journal of Dermatology, 2015, 173, 1546-1549.	1.5	261
89	Homozygous Missense Mutation in <i>IL36RN</i> in Generalized Pustular Dermatosis With Intraoral Involvement Compatible With Both AGEP and Generalized Pustular Psoriasis. JAMA Dermatology, 2015, 151, 452.	4.1	44
90	Definitions and outcome measures for mucous membrane pemphigoid: Recommendations ofÂanÂinternational panel of experts. Journal of the American Academy of Dermatology, 2015, 72, 168-174.	1.2	133

#	Article	IF	CITATIONS
91	Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. British Journal of Dermatology, 2015, 172, 867-877.	1.5	264
92	Cutaneous reactive angiomatosis with foreign body reaction after total knee replacement with a defective implant: a diagnostic challenge with a review of the literature. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1029-1032.	2.4	1
93	Erythrodermic Epidermolysis Bullosa Acquisita. JAMA Dermatology, 2015, 151, 678.	4.1	1
94	Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd: <scp>YAG</scp> laser: a prospective, comparative, randomized, openâ€label trial. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 549-554.	2.4	43
95	Efficacy of topical tacrolimus for oral lichen planus: realâ€life experience in a retrospective cohort of patients with a review of the literature. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1107-1113.	2.4	18
96	Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (<scp>EDF</scp>) in cooperation with the European Academy of Dermatology and Venereology (<scp>EADV</scp>). Journal of the European Academy of Dermatology and Venereology, 2015, 29, 405-414.	2.4	218
97	BPAG1a and b Associate with EB1 and EB3 and Modulate Vesicular Transport, Golgi Apparatus Structure, and Cell Migration in C2.7 Myoblasts. PLoS ONE, 2014, 9, e107535.	2.5	27
98	Systemic Light-Chain Amyloidosis Revealed by Progressive Nail Involvement, Diffuse Alopecia and Sicca Syndrome: Report of an Unusual Case with a Review of the Literature. Dermatology, 2014, 228, 97-102.	2.1	30
99	Late secondary syphilis with nodular lesions mimicking Kaposi sarcoma in a patient with human immunodeficiency virus. International Journal of Dermatology, 2014, 53, e71-e73.	1.0	7
100	A tattoo complicated by allergic contact dermatitis and panniculitis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 127-128.	2.4	8
101	Plakins, a Versatile Family of Cytolinkers: Roles in Skin Integrity and in Human Diseases. Journal of Investigative Dermatology, 2014, 134, 885-894.	0.7	103
102	Localized Epidermal Cysts as a Radiation Recall Phenomenon in a Melanoma Patient Treated with Radiotherapy and the BRAF Inhibitor Vemurafenib. Case Reports in Dermatology, 2014, 6, 213-217.	0.8	8
103	Toward a Practical Renaming of Bullous Pemphigoid and All Its Variants. JAMA Dermatology, 2014, 150, 459.	4.1	10
104	A New Light on an Old Disease: Adhesion Signaling in Pemphigus Vulgaris. Journal of Investigative Dermatology, 2014, 134, 8-10.	0.7	9
105	Acute peripheral unilateral facial nerve paralysis following minor surgery. European Journal of Dermatology, 2014, 24, 417-418.	0.6	1
106	Scarring and chronic ulceration of the floor of the mouth. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2014, 117, 267-271.	0.4	1
107	Interaction of Plectin with Keratins 5 and 14: Dependence on Several Plectin Domains and Keratin Quaternary Structure. Journal of Investigative Dermatology, 2014, 134, 2776-2783.	0.7	35
108	Effects of Systematic Patient Education in Skin Care and Protection in a Hand Eczema Clinic. Dermatology, 2014, 228, 220-224.	2.1	7

#	Article	IF	Citations
109	Laboratory diagnosis of paraneoplastic pemphigus. British Journal of Dermatology, 2013, 169, 1016-1024.	1.5	94
110	Bullous pemphigoid: therapeutic algorithm and practical management. Expert Opinion on Orphan Drugs, 2013, 1, 405-412.	0.8	1
111	Phosphorylation of serine 4642 in the COOH-extremity of plectin by MNK2 and PKA modulates its interaction with intermediate filaments. Journal of Cell Science, 2013, 126, 4195-207.	2.0	28
112	Severe cutaneous allergic reactions following topical antifungal therapy. Contact Dermatitis, 2013, 68, 56-57.	1.4	5
113	Giant Cellulitis-like Sweet Syndrome, a New Variant of Neutrophilic Dermatosis. JAMA Dermatology, 2013, 149, 79.	4.1	40
114	Docetaxel-induziertes Rezidiv eines subakuten kutanen Lupus erythematodes und eines Chilblain-Lupus. JDDG - Journal of the German Society of Dermatology, 2013, 11, 871-874.	0.8	0
115	Penile Erosions as First Manifestation of Pemphigus Vulgaris: A Misleading Presentation. Acta Dermato-Venereologica, 2013, 93, 248-249.	1.3	4
116	Glucocorticoids in Autoimmune Bullous Diseases: Are Neutrophils the Key Cellular Target?. Journal of Investigative Dermatology, 2013, 133, 2314-2315.	0.7	5
117	Anti-Alpha-2-Macroglobulin-Like-1 Autoantibodies Are Detected Frequently and May Be Pathogenic in Paraneoplastic Pemphigus. Journal of Investigative Dermatology, 2013, 133, 1785-1793.	0.7	47
118	Clinical challenges and recent advances in the diagnosis of bullous pemphigoid. Expert Review of Dermatology, 2013, 8, 407-416.	0.3	3
119	Acral Purpura as Leading Clinical Manifestation of Dermatitis Herpetiformis: Report of Two Adult Cases with a Review of the Literature. Dermatology, 2013, 227, 1-4.	2.1	25
120	Cutaneous Reactive Angiomatosis with Combined Histological Pattern Mimicking a Cellulitis. Dermatology, 2013, 227, 226-230.	2.1	13
121	Facial Basal Cell Carcinomas Recurring after Photodynamic Therapy: A Retrospective Analysis of Histological Subtypes. Dermatology, 2012, 224, 346-351.	2.1	38
122	Endemic Pemphigus Foliaceus: Towards Understanding Autoimmune Mechanisms of Disease Development. Journal of Investigative Dermatology, 2012, 132, 2499-2502.	0.7	11
123	Oral Mucosal Morphea: A New Variant. Dermatology, 2012, 224, 215-220.	2.1	13
124	Mortality Rate in Bullous Pemphigoid: A Retrospective Monocentric Cohort Study. Dermatology, 2012, 225, 320-325.	2.1	34
125	Linear IgA bullous dermatosis mimicking a neutrophilic dermatosis. European Journal of Dermatology, 2012, 22, 713-714.	0.6	5
126	Bullous Pemphigoid: Simple Measures for a Complex Disease. Journal of Investigative Dermatology, 2012, 132, 1948-1950.	0.7	4

#	Article	IF	Citations
127	Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts. Journal of the American Academy of Dermatology, 2012, 66, 479-485.	1.2	294
128	Bullous pemphigoid: From the clinic to the bench. Clinics in Dermatology, 2012, 30, 3-16.	1.6	123
129	Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort. British Journal of Dermatology, 2012, 167, 1111-1117.	1.5	86
130	Evidence-Based Management of Bullous Pemphigoid. Dermatologic Clinics, 2011, 29, 613-620.	1.7	33
131	Clinical Features and Practical Diagnosis of Bullous Pemphigoid. Dermatologic Clinics, 2011, 29, 427-438.	1.7	99
132	Oral Mucous Membrane Pemphigoid: Complete Response to Topical Tacrolimus. Acta Dermato-Venereologica, 2011, 91, 604-605.	1.3	16
133	Linear sclerodermic lupus erythematosus, a distinct variant of linear morphea and chronic cutaneous lupus erythematous. International Journal of Dermatology, 2011, 50, 1491-1495.	1.0	10
134	Mortality of bullous pemphigoid in Switzerland: a prospective study. British Journal of Dermatology, 2011, 165, 368-374.	1.5	80
135	Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis. British Journal of Dermatology, 2011, 165, 1133-1137.	1.5	55
136	Plectin interacts with the rod domain of type III intermediate filament proteins desmin and vimentin. European Journal of Cell Biology, 2011, 90, 390-400.	3.6	42
137	Autoimmune Progesterone Dermatitis: Potential Role of Cutaneous Angiogenin Expression?. Dermatology, 2011, 223, 32-35.	2.1	10
138	Demonstration of Epitope-Spreading Phenomena in Bullous Pemphigoid: Results of a Prospective Multicenter Study. Journal of Investigative Dermatology, 2011, 131, 2271-2280.	0.7	132
139	Sensitivity of Immunofluorescence Studies vs Enzyme-Linked Immunosorbent Assay for Diagnosis of Bullous Pemphigoid. Archives of Dermatology, 2011, 147, 1454.	1.4	3
140	Rituximab for Severe Mucous Membrane Pemphigoid. Archives of Dermatology, 2011, 147, 855.	1.4	9
141	Hairy Pinnae after Orchiectomy and Chemotherapy for Testicular Cancer: Acquired Localized Hypertrichosis of the Ears. Dermatology, 2011, 222, 289-291.	2.1	6
142	Amicrobial Pustulosis-Like Rash in a Patient with Crohn's Disease under Anti-TNF-Alpha Blocker. Dermatology, 2011, 222, 304-310.	2.1	30
143	Bullous Pemphigoid: Clinical Features, Diagnostic Markers, and Immunopathogenic Mechanisms. , 2011, , 65-95.		1
144	Specific Nail Alterations in Cutaneous T-Cell Lymphoma. Archives of Dermatology, 2010, 146, 1287-91.	1.4	14

#	Article	IF	Citations
145	Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Clinical Immunology, 2010, 134, 320-330.	3.2	64
146	BPAG1 isoform-b: Complex distribution pattern in striated and heart muscle and association with plectin and \hat{l}_{\pm} -actinin. Experimental Cell Research, 2010, 316, 297-313.	2.6	25
147	â€~Bullous' Pemphigoid: What Are You? Urgent Need of Definitions and Diagnostic Criteria. Dermatology, 2010, 221, 131-134.	2.1	18
148	EpiDex® Swiss Field Trial 2004–2008. Dermatology, 2010, 221, 365-372.	2.1	45
149	Evidence for a New Fumarate Hydratase Gene Mutation in a Unilateral Type 2 Segmental Leiomyomatosis. Dermatology, 2010, 221, 149-153.	2.1	7
150	The Protease Inhibitor Alpha-2-Macroglobuline-Like-1 Is the p170 Antigen Recognized by Paraneoplastic Pemphigus Autoantibodies in Human. PLoS ONE, 2010, 5, e12250.	2.5	98
151	Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. British Journal of Dermatology, 2009, 161, 861-868.	1.5	228
152	Recommendations for the use of rituximab (antiâ€CD20 antibody) in the treatment of autoimmune bullous skin diseases [§] . JDDG - Journal of the German Society of Dermatology, 2008, 6, 366-373.	0.8	144
153	Rituximab Immunotherapy in Pemphigus: Therapeutic Effects Beyond B-Cell Depletion. Journal of Investigative Dermatology, 2008, 128, 2745-2747.	0.7	47
154	A rare tumour of the nail apparatus: onychomatricoma. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 1127-1128.	2.4	13
155	Simultaneous manifestation of variegate porphyria in monozygotic twins. British Journal of Dermatology, 2008, 159, 503-505.	1.5	3
156	Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clinical Immunology, 2008, 128, 415-426.	3.2	173
157	Chronic Hemicorporal Prurigo Related to a Posttraumatic Brown-Sé quard Syndrome. Dermatology, 2008, 217, 45-47.	2.1	22
158	Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. Journal of the American Academy of Dermatology, 2008, 58, 1043-1046.	1.2	464
159	Orodigital Pemphigus Vulgaris: A Pathogenic Role of Anti-Desmoglein-3 Autoantibodies in Pemphigus Paronychia?. Dermatology, 2008, 217, 337-339.	2.1	4
160	Primary Atrophic Solitary Morphea Profunda. Dermatology, 2008, 217, 207-210.	2.1	16
161	Subungual Exostosis. New England Journal of Medicine, 2008, 359, e31.	27.0	9
162	Value of a Novel Neisseria Meningitidis–Specific Polymerase Chain Reaction Assay in Skin Biopsy Specimens as a Diagnostic Tool in Chronic Meningococcemia. Archives of Dermatology, 2008, 144, 770-3.	1.4	31

#	Article	IF	CITATIONS
163	Mucocutaneous Lichen Planus With Esophageal Involvement. Archives of Dermatology, 2008, 144, 1427.	1.4	37
164	Rituximab (Anti-CD20 Monoclonal Antibody) – Ultimate or First Choice in Pemphigus?. Dermatology, 2007, 214, 275-277.	2.1	16
165	Bullous Pemphigoid: Physiopathology, Clinical Features and Management. Advances in Dermatology, 2007, 23, 257-288.	2.0	101
166	Multiple cutaneous osteomas of the face associated with chronic inflammatory acne. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 321-326.	2.4	42
167	Widespread skin necrosis associated with unfractionated heparin therapy in a patient under chronic coumarin anticoagulation. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 327-330.	2.4	8
168	Acquired Melanocytic Naevus in Childhood Vulval Pemphigoid. Dermatology, 2006, 213, 159-162.	2.1	19
169	Focal Palmoplantar Keratoderma Caused by an Autosomal Dominant Inherited Mutation in the Desmoglein 1 Gene. Dermatology, 2006, 212, 117-122.	2.1	36
170	New insights into the molecular basis of desmoplakinand desmin-related cardiomyopathies. Journal of Cell Science, 2006, 119, 4974-4985.	2.0	57
171	Autoreactive T and B Cells from Bullous Pemphigoid (BP) Patients Recognize Epitopes Clustered in Distinct Regions of BP180 and BP230. Journal of Immunology, 2006, 176, 2015-2023.	0.8	110
172	Bullous pemphigoid antigen 1 isoforms: potential new target autoantigens in multiple sclerosis?. British Journal of Dermatology, 2005, 152, 537-540.	1.5	55
173	Comparative analysis of the expression of ERBIN and Erb-B2 in normal human skin and cutaneous carcinomas British Journal of Dermatology, 2005, 152, 1248-1255.	1.5	22
174	Calcifying panniculitis following subcutaneous injections of nadroparin-calcium in a patient with osteomalacia. British Journal of Dermatology, 2005, 153, 657-660.	1.5	29
175	The Z-disc proteins myotilin and FATZ-1 interact with each other and are connected to the sarcolemma via muscle-specific filamins. Journal of Cell Science, 2005, 118, 3739-3749.	2.0	115
176	A Case of Amicrobial Pustulosis of the Folds Associated with Neutrophilic Gastrointestinal Involvement in Systemic Lupus Erythematosus. Dermatology, 2005, 211, 356-359.	2.1	37
177	Shedding of Collagen XVII/BP180. Journal of Biological Chemistry, 2004, 279, 24521-24529.	3.4	71
178	Localized Childhood Vulval Pemphigoid Treated with Tacrolimus Ointment. Dermatology, 2004, 208, 273-275.	2.1	27
179	Acute pustulosis of the legs in diverticulitis with sigmoid stenosis: an overlap between bowelâ€associated dermatosis–arthritis syndrome and pustular pyoderma gangrenosum. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 89-92.	2.4	31
180	Childhood Bullous Pemphigoid: Report of a Case with Life-Threatening Course During Homeopathy Treatment. Pediatric Dermatology, 2004, 21, 160-163.	0.9	40

#	Article	IF	CITATIONS
181	BP230- and BP180-specific Auto-Antibodies in Bullous Pemphigoid. Journal of Investigative Dermatology, 2004, 122, 1413-1422.	0.7	118
182	Molecular Consequences of Deletion of the Cytoplasmic Domain of Bullous Pemphigoid 180 in a Patient with Predominant Features of Epidermolysis Bullosa Simplex. Journal of Investigative Dermatology, 2004, 122, 65-72.	0.7	22
183	Characterization of the Anti-BP180 Autoantibody Reactivity Profile and Epitope Mapping in Bullous Pemphigoid Patients11Tables 1, 2, 3 and 5 can be found at http://www.blackwellpublishing.com/products/journals/suppmat/jid/jid22126/jid22126sm.htm. Journal of Investigative Dermatology, 2004, 122, 103-110.	0.7	89
184	In Vitro Methods for Investigating Desmoplakin–Intermediate Filament Interactions and Their Role in Adhesive Strength. Methods in Cell Biology, 2004, 78, 757-786.	1.1	21
185	An unusual form of primary systemic amyloidosis: amyloid elastosis: report of a case treated by haematopoietic cell transplantation. British Journal of Dermatology, 2003, 148, 154-159.	1.5	27
186	Diagnostic value of an enzyme-linked immunosorbent assay using BP180 recombinant proteins in elderly patients with pruritic skin disorders. British Journal of Dermatology, 2003, 149, 910-912.	1.5	29
187	Production of the bullous pemphigoid antigen 230 (BP230) by Saccharomyces cerevisiae and Pichia pastoris. Protein Expression and Purification, 2003, 29, 141-147.	1.3	2
188	Interaction of the Bullous Pemphigoid Antigen 1 (BP230) and Desmoplakin with Intermediate Filaments Is Mediated by Distinct Sequences within Their COOH Terminus. Molecular Biology of the Cell, 2003, 14, 1978-1992.	2.1	98
189	Analysis of the interactions between BP180, BP230, plectin and the integrin $\hat{l}\pm6\hat{l}^24$ important for hemidesmosome assembly. Journal of Cell Science, 2003, 116, 387-399.	2.0	206
190	Multiple Hyperkeratotic Spicules and Myeloma. Dermatology, 2002, 205, 210-212.	2.1	20
191	Drug-induced epidermolysis bullosa acquisita with antibodies to type VII collagen. Journal of the American Academy of Dermatology, 2002, 46, S161-S164.	1.2	35
192	Anti-glomerular basement membrane nephritis and bullous pemphigoid caused by distinct anti-α3(IV)NC1 and anti-BP180 antibodies in a patient with Crohn's disease. American Journal of Kidney Diseases, 2002, 40, 649-654.	1.9	26
193			
	Deletion of the Cytoplasmatic Domain of BP180/Collagen XVII Causes a Phenotype with Predominant Features of Epidermolysis Bullosa Simplex. Journal of Investigative Dermatology, 2002, 118, 185-192.	0.7	45
194	Deletion of the Cytoplasmatic Domain of BP180/Collagen XVII Causes a Phenotype with Predominant Features of Epidermolysis Bullosa Simplex. Journal of Investigative Dermatology, 2002, 118, 185-192. Severity and Phenotype of Bullous Pemphigoid Relate to Autoantibody Profile Against the NH2- and COOH-Terminal Regions of the BP180 Ectodomain. Journal of Investigative Dermatology, 2002, 119, 1065-1073.	0.7	166
194 195	Features of Epidermolysis Bullosa Simplex. Journal of Investigative Dermatology, 2002, 118, 185-192. Severity and Phenotype of Bullous Pemphigoid Relate to Autoantibody Profile Against the NH2- and COOH-Terminal Regions of the BP180 Ectodomain. Journal of Investigative Dermatology, 2002, 119,		
	Features of Epidermolysis Bullosa Simplex. Journal of Investigative Dermatology, 2002, 118, 185-192. Severity and Phenotype of Bullous Pemphigoid Relate to Autoantibody Profile Against the NH2- and COOH-Terminal Regions of the BP180 Ectodomain. Journal of Investigative Dermatology, 2002, 119, 1065-1073. Erosive pustular dermatosis of the leg: report of three cases. British Journal of Dermatology, 2002,	0.7	166
195	Features of Epidermolysis Bullosa Simplex. Journal of Investigative Dermatology, 2002, 118, 185-192. Severity and Phenotype of Bullous Pemphigoid Relate to Autoantibody Profile Against the NH2- and COOH-Terminal Regions of the BP180 Ectodomain. Journal of Investigative Dermatology, 2002, 119, 1065-1073. Erosive pustular dermatosis of the leg: report of three cases. British Journal of Dermatology, 2002, 147, 765-769. Pyogenic granuloma-like lesions during capecitabine therapy. British Journal of Dermatology, 2002,	0.7	166 47

#	Article	IF	CITATIONS
199	Plectin, an unusual target antigen in bullous pemphigoid. British Journal of Dermatology, 2001, 144, 136-138.	1.5	22
200	Autoantibodies to the extracellular and intracellular domain of bullous pemphigoid 180, the putative key autoantigen in bullous pemphigoid, belong predominantly to the IgG1 and IgG4 subclasses. British Journal of Dermatology, 2001, 144, 760-768.	1.5	49
201	IgG, IgA and IgE autoantibodies against the ectodomain of desmoglein 3 in active pemphigus vulgaris. British Journal of Dermatology, 2001, 144, 1183-1188.	1.5	75
202	Schonlein-Henoch purpura associated with losartan treatment and presence of antineutrophil cytoplasmic antibodies of x specificity. British Journal of Dermatology, 2001, 145, 362-363.	1.5	14
203	Respective Contribution of Neutrophil Elastase and Matrix Metalloproteinase 9 in the Degradation of BP180 (Type XVII Collagen) in Human Bullous Pemphigoid. Journal of Investigative Dermatology, 2001, 117, 1091-1096.	0.7	100
204	Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. American Journal of Hematology, 2001, 66, 142-144.	4.1	171
205	The Hemidesmosomal Protein Bullous Pemphigoid Antigen 1 and the Integrin Î ² 4 Subunit Bind to ERBIN. Journal of Biological Chemistry, 2001, 276, 32427-32436.	3.4	73
206	Acute Genitocrural Intertrigo: A Sign of Primary Human Immunodeficiency Virus Type 1 Infection. Dermatology, 2001, 203, 171-173.	2.1	8
207	Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Archives of Dermatology, 2001, 137, 269-72.	1.4	92
208	IgG Autoantibodies from Bullous Pemphigoid Patients Recognize Multiple Antigenic Reactive Sites Located Predominantly Within the B and C Subdomains of the COOH-Terminus of BP230. Journal of Investigative Dermatology, 2000, 114, 998-1004.	0.7	85
209	IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis. British Journal of Dermatology, 2000, 143, 349-355.	1.5	96
210	Takayasu Arteritis and Cutaneous Necrotizing Vasculitis. Dermatology, 2000, 200, 139-143.	2.1	41
211	Plantar Erythema nodosum in a Patient with Crohnâ€s Disease. Dermatology, 1999, 199, 190-190.	2.1	2
212	IgG Autoantibodies from Bullous Pemphigoid (BP) Patients Bind Antigenic Sites on Both the Extracellular and the Intracellular Domains of the BP Antigen 180. Journal of Investigative Dermatology, 1999, 112, 141-147.	0.7	106
213	Structure and Function of Hemidesmosomes: More Than Simple Adhesion Complexes. Journal of Investigative Dermatology, 1999, 112, 411-418.	0.7	513
214	Interaction of BP180 and $\hat{l}\pm6\hat{l}^24$. Journal of Investigative Dermatology, 1999, 112, 830-831.	0.7	6
215	Childhood bullous pemphigoid: Report of a case with characterization of the targeted antigens. Journal of the American Academy of Dermatology, 1999, 40, 338-344.	1.2	46
216	IgG Autoantibodies from a Lichen planus pemphigoides Patient Recognize the NC16A Domain of the Bullous Pemphigoid Antigen 180. Dermatology, 1999, 199, 253-255.	2.1	25

#	Article	IF	Citations
217	Autoantibodies from a Patient with Paraneoplastic Pemphigus Bind Periplakin, a Novel Member of the Plakin Family. Journal of Investigative Dermatology, 1998, 111, 338-340.	0.7	51
218	Treatment of primary anetoderma with colchicine. Journal of the American Academy of Dermatology, 1998, 38, 1002-1003.	1.2	26
219	Role of the Bullous Pemphigoid Antigen 180 (BP180) in the Assembly of Hemidesmosomes and Cell Adhesion—Reexpression of BP180 in Generalized Atrophic Benign Epidermolysis Bullosa Keratinocytes. Experimental Cell Research, 1998, 239, 463-476.	2.6	59
220	Hemidesmosome Formation Is Initiated by the \hat{l}^24 Integrin Subunit, Requires Complex Formation of \hat{l}^24 and HD1/Plectin, and Involves a Direct Interaction between \hat{l}^24 and the Bullous Pemphigoid Antigen 180. Journal of Cell Biology, 1998, 142, 271-284.	5.2	171
221	Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls Journal of Clinical Investigation, 1998, 102, 2082-2089.	8.2	201
222	The Localization of Bullous Pemphigoid Antigen 180 (BP180) in Hemidesmosomes Is Mediated by Its Cytoplasmic Domain and Seems to be Regulated by the \hat{I}^2 4 Integrin Subunit. Journal of Cell Biology, 1997, 136, 1333-1347.	5.2	121
223	The Extracellular Domain of BPAG2 Localizes to Anchoring Filaments and its Carboxyl Terminus Extends to the Lamina Densa of Normal Human Epidermal Basement Membrane. Journal of Investigative Dermatology, 1997, 109, 200-206.	0.7	99
224	The subcellular distribution of the high molecular mass protein, HD1, is determined by the cytoplasmic domain of the integrin \hat{l}^24 subunit. Journal of Cell Science, 1997, 110, 169-178.	2.0	37
225	Hemidesmosomes: roles in adhesion, signaling and human diseases. Current Opinion in Cell Biology, 1996, 8, 647-656.	5.4	207
226	Genomic Organization of the Mouse \hat{l}^21 Gene: Conservation of the \hat{l}^21D but not of the \hat{l}^21B and \hat{l}^21C Integrin Splice Variants. Cell Adhesion and Communication, 1996, 4, 1-11.	1.7	26
227	Passive transfer of autoantibodies from a patient with mutilating epidermolysis bullosa acquisita induces specific alterations in the skin of neonatal mice. Archives of Dermatology, 1995, 131, 590-5.	1.4	9
228	IgM autoantibodies to 180- and 230- to 240-kd human epidermal proteins in pregnancy. Archives of Dermatology, 1995, 131, 43-7.	1.4	0
229	Penicilliosis marneffei infection in AIDS. Journal of the American Academy of Dermatology, 1994, 31, 843-846.	1.2	39
230	PAPULAR-PURPURIC "GLOVES AND SOCKS" SYNDROME. International Journal of Dermatology, 1994, 33, 196-197.	1.0	12
231	Annular bullous eruption in a patient with the CREST syndrome, primary biliary cirrhosis, and Sjögren's syndrome. Journal of the American Academy of Dermatology, 1993, 29, 648-650.	1.2	1
232	Skin manifestations of cardio-facio-cutaneous syndrome. Journal of the American Academy of Dermatology, 1993, 28, 815-819.	1.2	43
233	Bullous Systemic Lupus erythematosus. Dermatology, 1993, 187, 306-308.	2.1	6
234	Mycetoma of the Foot due to <i>Fusarium </i> sp. Treated with Oral Ketoconazole. Dermatology, 1992, 184, 303-305.	2.1	18

#	Article	IF	CITATIONS
235	Acral Persistent Papular Mucinosis and IgA Monoclonal Gammopathy: Report of a Case. Dermatology, 1992, 185, 134-136.	2.1	30
236	Localized pretibial pemphigoid and pemphigoid nodularis. Journal of the American Academy of Dermatology, 1992, 27, 863-867.	1.2	36
237	Oral intraepidermal IgA pustulosis and Crohn's disease. British Journal of Dermatology, 1992, 126, 383-386.	1.5	35
238	Urticarial vasculitis associated with a monoclonal IgM gammopathy: Schnitzler's syndrome. British Journal of Dermatology, 1990, 123, 113-118.	1.5	75
239	Hereditary Angioedema and Oral Contraception. Dermatology, 1990, 181, 78-79.	2.1	16
240	Combined complete C5 and partial C4 deficiency in humans: Clinical consequences and complement-mediated functions in vitro. Clinical Immunology and Immunopathology, 1990, 55, 41-55.	2.0	21
241	Clinical significance of platelet-associated immunoglobulins in narcotic addicts with human immunodeficiency virus infection. Clinical Immunology and Immunopathology, 1990, 54, 256-265.	2.0	11
242	Pemphigoid nodularis. Archives of Dermatology, 1990, 126, 1522-1523.	1.4	20
243	Relative importance of total versus external platelet-associated IgG. Blut, 1989, 59, 67-74.	1.2	6
244	Metastatic Eccrine Sweat Gland Carcinoma: Case Report. Dermatology, 1988, 177, 295-299.	2.1	18
245	Influence of Exogenous Interleukin-2 on the Proliferation of Lymphocytes from Normal Donors and from Patients after Autologous Bone Marrow Transplantation. Acta Haematologica, 1987, 77, 129-134.	1.4	3
246	Comorbidities in lichen planus by phenomeâ€wide association study in two biobank population cohorts. British Journal of Dermatology, 0, , .	1.5	2
247	Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms. Frontiers in Immunology, 0, 13, .	4.8	14